Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levonordefrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonordefrin SCHEMBL6295856 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL14478222 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL14478226 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL29693041 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL29410156 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL249722 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL1780761 | 1.00 | TDP1 (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL316522 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Levonordefrin SCHEMBL363800 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA | |
| Nordefrin SCHEMBL5060952 | 0.98 | KDM4E (1.00) | TDP1KDM4ERECQLMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432401-B1 | — | — | None | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4694929-A1 | METHODS FOR TREATING CORNEAL INJURIES | Lin, Sung-Jan (TW) | 2026-02-18 | — | — | EP | claimed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| WO-2025233438-A1 | POXVIRAL RNA-POLYMERASE COMPLEXES | JULIUS-MAXIMILIANS-UNIVERSITÄT, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-11-13 | — | — | WO | claimed |
| US-20250255755-A1 | WOUND HEALING DEVICE AND METHODS FOR WOUND HEALING | SINUS CLEAR INNOVATIONS LLC (US) | 2025-08-14 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20020183396-A1 | Administering to a mammal in need of an anesthetic agent and an alpha adrenergic receptor agonist to the site to be anesthetized to constrict the blood vessels at the site and prolong the local anestheia, then administering an antagonist | NOVALAR PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020161018-A1 | Enhancement of the potency and efficacy of local anesthetics with ibutilide and other methanesulfonamide drugs | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-10-31 | — | — | US | claimed |
| WO-2002067896-A1 | IBUTILIDE AND METHANESULFONAMIDE FOR LOCAL ANESTHETICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-09-06 | — | — | WO | claimed |
| US-6432401-B2 | ADMINISTERING A LOCAL ANESTHETIC AND ALPHA ADRENERGIC RECEPTOR AGONIST TO INDUCE LOCAL ANESTHESIA FOLLOWED BY REVERSING ANESTHESIA WITH A LOW DOSE OF AN ALPHA ADRENERGIC RECEPTOR ANTAGONIST; USE IN HAIR GRAFT PROCEDURES, FOR EXAMPLE | NOVALAR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | claimed |
| US-20010056125-A1 | Local anesthetic methods and kits | NOVALAR PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | claimed |
| WO-2001085171-A1 | LOCAL ANESTHETIC METHODS AND KITS | NOVALAR PHARMACEUTICALS, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-5676691-A | Treatment of vascular and tension headache, atypical facial pain, and cervical muscle hyperactivity | FRIEDMAN MARK H (US) | 1997-10-14 | — | — | US | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0059057-A1 | Treatment of diarrhoea | BEECHAM GROUP PLC (GB) | 1982-09-01 | — | — | EP | claimed |
| US-4313956-A | Novel sypathomimetic amine prodrugs | INTERX RESEARCH CORP. (US) | 1982-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADRA2A 1485/4885ADRA2C 744/4885ADRA2B 1919/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | ADRA2A 1492/4885ADRA2C 641/4885ADRA2B 1756/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADRA2A 1485/4885ADRA2C 744/4885ADRA2B 1919/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ADRA2A 190/4885ADRA2C 304/4885ADRA2B 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.